已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and safety of high-dose esomeprazole–amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial

埃索美拉唑 医学 阿莫西林 内科学 幽门螺杆菌 胃肠病学 呋喃唑酮 意向治疗分析 不利影响 随机对照试验 临床终点 抗生素 微生物学 生物
作者
Hanxin Bi,Xingxing Chen,Yuxin Chen,Xin Zhao,Shasha Wang,Jiehong Wang,Ting Lyu,Shuang Han,Tao Lin,Mingquan Li,Donghong Yuan,Junye Liu,Yongquan Shi
出处
期刊:Chinese Medical Journal [Lippincott Williams & Wilkins]
卷期号:135 (14): 1707-1715 被引量:21
标识
DOI:10.1097/cm9.0000000000002289
摘要

High-dose dual therapy (HDDT) with proton pump inhibitors (PPIs) and amoxicillin has attracted widespread attention due to its favorable efficacy in eradicating Helicobacter pylori (H. pylori). This study aimed to compare the efficacy and safety of high-dose PPI-amoxicillin dual therapy and bismuth-containing quadruple therapy for H. pylori rescue treatment.This was a prospective, randomized, multicenter, non-inferiority trial. Patients recruited from eight centers who had failed previous treatment were randomly (1:1) allocated to two eradication groups: HDDT (esomeprazole 40 mg and amoxicillin 1000 mg three times daily; the HDDT group) and bismuth-containing quadruple therapy (esomeprazole 40 mg, bismuth potassium citrate 220 mg, and furazolidone 100 mg twice daily, combined with tetracycline 500 mg three times daily; the tetracycline, furazolidone, esomeprazole, and bismuth [TFEB] group) for 14 days. The primary endpoint was the H. pylori eradication rate. The secondary endpoints were adverse effects, symptom improvement rates, and patient compliance.A total of 658 patients who met the criteria were enrolled in this study. The HDDT group achieved eradication rates of 75.4% (248/329), 81.0% (248/306), and 81.3% (248/305) asdetermined by the intention-to-treat (ITT), modified intention-to-treat (MITT), and per-protocol (PP) analyses, respectively. The eradication rates were similar to those in the TFEB group: 78.1% (257/329), 84.2% (257/305), and 85.1% (257/302). The lower 95% confidence interval boundary (-9.19% in the ITT analysis, - 9.21% in the MITT analysis, and -9.73% in the PP analysis) was greater than the predefined non-inferiority margin of -10%, establishing a non-inferiority of the HDDT group vs. the TFEB group. The incidence of adverse events in the HDDT group was significantly lower than that in the TFEB group (11.1% vs. 26.8%, P < 0.001). Symptom improvement rates and patients' compliance were similar between the two groups.Fourteen-day HDDT is non-inferior to bismuth-containing quadruple therapy, with fewer adverse effects and good treatment compliance, suggesting HDDT as an alternative for H. pylori rescue treatment in the local region.Clinicaltrials.gov, NCT04678492.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
南风知我意完成签到 ,获得积分10
刚刚
1秒前
2秒前
今后应助冷傲的水儿采纳,获得10
3秒前
homie发布了新的文献求助10
4秒前
4秒前
双椒兔丁完成签到,获得积分10
4秒前
NexusExplorer应助Ramer556采纳,获得10
5秒前
猪蹄发布了新的文献求助10
6秒前
直觉发布了新的文献求助10
7秒前
土豆发布了新的文献求助10
8秒前
一直向前发布了新的文献求助10
12秒前
12秒前
丘比特应助十四采纳,获得10
14秒前
14秒前
霜序完成签到,获得积分10
15秒前
16秒前
21秒前
23秒前
大模型应助小燕子采纳,获得10
25秒前
斯文的萧完成签到,获得积分10
25秒前
十四发布了新的文献求助10
26秒前
直觉发布了新的文献求助10
27秒前
27秒前
29秒前
小蘑菇应助漂亮白枫采纳,获得10
30秒前
Hello应助漂亮白枫采纳,获得10
30秒前
李健应助欣慰的剑鬼采纳,获得10
30秒前
小刘发布了新的文献求助10
32秒前
35秒前
36秒前
张昭蓉完成签到 ,获得积分10
37秒前
miles发布了新的文献求助10
41秒前
Hello应助猪蹄采纳,获得10
41秒前
顾众生发布了新的文献求助10
43秒前
43秒前
天天快乐应助科研通管家采纳,获得10
46秒前
Jasper应助科研通管家采纳,获得10
46秒前
深情安青应助科研通管家采纳,获得10
46秒前
46秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989868
求助须知:如何正确求助?哪些是违规求助? 3531994
关于积分的说明 11255752
捐赠科研通 3270793
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882215
科研通“疑难数据库(出版商)”最低求助积分说明 809208